Hi there,

This month, Democracy Now! marks 29 years of fearless independent journalism. Presidents have come, gone and come back again, but Democracy Now! remains, playing the same critical role in our democracy: shining a spotlight on corporate and government abuses of power and raising up the voices of scholars, advocates, scientists, activists, artists and ordinary people working for a more peaceful and just world. Thanks to a group of generous donors, all donations made today will be DOUBLED, which means your $15 gift is worth $30. If our journalism is important to you, please donate today in honor of our 29th anniversary. Every dollar makes a difference. Thank you so much.

Democracy Now!

Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.

Donate

House Democrats Grill Pharmaceutical Executives over Skyrocketing Drug Prices

HeadlineOct 01, 2020

On Capitol Hill, House Democrats grilled drug company executives Wednesday over soaring prescription drug prices, which are far higher in the U.S. than anywhere else in the world. This is California Congressmember Katie Porter questioning Celgene CEO Mark Alles over the skyrocketing price of the cancer drug Revlimid, which now costs more than triple what it did 15 years ago.

Rep. Katie Porter: “Mr. Alles, do you know how much you personally received in bonuses over two years, the last two years, just because Celgene raised the price of this one drug, Revlimid?”

Mark Alles: “I receive very generous compensation, but I don’t know the exact number that you’re referring to.”

Rep. Katie Porter: “In fact, you personally received half a million dollars, personally, just by tripling the price of Revlimid. So, to recap here, the drug didn’t get any better. The cancer patients didn’t get any better. You just got better at making money. You just refined your skills at price gouging. And to be clear, the taxpayers spent $3.3 billion on Revlimid.”

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation
Top